The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

PATIENTS REPORT IMPROVED QUALITY OF LIFE1

Sustained improvement in physical function up to 5 years1,a

Line graph showing sustained improvement in physical function for up to 5 years. Please see full Important Safety Information.

aPALACE 1-3 pooled analysis. Data as observed; includes all patients who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA or were placebo patients re-randomized to OTEZLA at week 16 or week 24. Randomized patients who received ≥1 dose of study medication: OTEZLA 30 mg BID, n = 497; placebo, n = 498. The n at each time point represents the number of patients with available data at the time point.

OTEZLA improves physical function, relieves pain, and reduces fatigue2-5

  • Patients taking OTEZLA 30 mg BID achieved significant improvement in quality of life, as measured by reduction in HAQ-DI (disability) score, vs placebo at week 166*

OTEZLA relieved fatigue and reduced pain

  • Patients taking OTEZLA 30 mg BID achieved significant improvements in baseline FACIT-F fatigue scores vs placebo at week 16, with an overall improvement of 5.7 points at 4 years7†
  • Patients taking OTEZLA 30 mg BID achieved significantly greater reductions in baseline pain VAS score vs placebo at week 16, with an overall reduction of -17.4 at 1 year

*PALACE 1 study. OTEZLA 30 mg BID vs placebo: -0.24 vs -0.09 (ITT, P = 0.0017).

Pooled analysis of PALACE 1-3. Week 16 improvement in FACIT-F score, OTEZLA 30 mg BID vs placebo: 3.45 (n = 473) vs 1.14 (n = 475); P < 0.001.

Pooled analysis of PALACE 1-3. Week 16 improvement in pain VAS score, OTEZLA 30 mg BID vs placebo: -12.7 (n = 472) vs -5.8 (n = 480), P < 0.0001.

§Patients randomized to OTEZLA 30 mg BID at baseline who remained on treatment for 52 weeks.

BID, twice daily; FACIT-F, Functional Assessment of Chronic Illness Therapy–Fatigue; HAQ-DI, Health Assessment Questionnaire–Disability Index; ITT, intent to treat; MCID; minimal clinically important difference; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy; VAS, visual analog scale.

References:

  1. Kavanaugh A, Gladman DD, Edwards CJ, et al. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis. Arthritis Res Ther. 2019;21(1):118.
  2. Mease PJ, Wollenhaupt J, Hall S, et al. Assessment of Disability Levels in a Cohort of 1,489 Patients With Active Psoriatic Arthritis, and the Effect of Apremilast Treatment: Pooled Data From Three Phase III, Randomized, Controlled Trials. Presented at: the 2015 ACR/ARHP Annual Meeting; November 7-11, 2015; San Francisco, CA.
  3. Kavanaugh A, Gladman DD, Edwards CJ, et al. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-term (104-Week) Improvement in Fatigue in Patients With Psoriatic Arthritis: Pooled Results From 3 Phase 3, Randomized, Controlled Trials. Presented at: the 2015 ACR/ARHP Annual Meeting; November 7-11, 2015; San Francisco, CA.
  4. Kavanaugh A, Gladman DD, Gomez-Reino JJ, et al. Long-term (156-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1). Presented at: the Annual European Congress of Rheumatology EULAR 2016; 8-11 June 2016; London, UK.
  5. Gladman D, Strand V, Kavanaugh A, et al. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated With Improvement of Pain, Fatigue, and Disability for Up to 52 Weeks in Patients With Psoriatic Arthritis: Results From 3 Phase 3, Randomized, Controlled Trials. Presented at: the 2014 ACR/ARHP Annual Meeting; November 15-19, 2014; Boston, MA.
  6. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020-1026.
  7. Kavanaugh A, Chen P, Fang L, et al. Durability of apremilast response in patients with psoriatic arthritis: long-term (208-week) results from the PALACE 1 trial. Ann Rheum Dis. 2017;76 (suppl 2): Abstract SAT0436.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.